Plasma Levels of CXCL1 (GRO-α) and CXCL10 (IP-10) are Elevated in Type 2 Diabetic Patients: Evidence for the Involvement of Inflammation and Angiogenesis / Angiostasis in this Disease State

Abstract

BACKGROUND: Recent evidence has demonstrated that environment and genetic factors play pivotal roles in diabetes and its related complications. The significant contributory role of cytokines in pathogenesis of type 2 diabetes is also well documented. This study was aimed to examine and compare both CXCL1 (GRO-alpha) and CXCL10 (IP-10) circulating levels in type 2 diabetic patients and healthy controls. METHODS: Peripheral blood samples were collected from 100 type 2 diabetic patients and 150 healthy controls. Circulating CXCL1 and CXCL10 levels were measured by ELISA. RESULTS: Elevated serum levels of both CXCL1 and CXCL10 were found in type 2 diabetic patients in comparison to controls. CONCLUSIONS: Elevated levels of CXCL1 and CXCL10 could possibly be used as a marker of inflammation and angiogenesis/angiostasis in type 2 diabetes.